{
    "Trade/Device Name(s)": [
        "HemosIL D-Dimer HS"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K151534",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070927"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "June 5, 2015",
    "Summary Letter Received Date": "June 8, 2015",
    "Submission Date": "June 5, 2015",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/fibrin degradation products assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "D-Dimer"
    ],
    "Specimen Type(s)": [
        "Citrated Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family"
    ],
    "Method(s)/Technology(ies)": [
        "Automated latex enhanced immunoassay",
        "Turbidimetric immunoassay"
    ],
    "Methodologies": [
        "Latex-enhanced immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL D-Dimer HS latex enhanced immunoassay for quantitative D-Dimer measurement in plasma to exclude VTE in suspected DVT and PE outpatients",
    "Indications for Use Summary": "Automated latex enhanced immunoassay for quantitative determination of D-Dimer in human citrated plasma on the ACL TOP, used with clinical pretest probability assessment to exclude venous thromboembolism (VTE) in outpatients suspected of deep vein thrombosis (DVT) and pulmonary embolism (PE)",
    "fda_folder": "Hematology"
}